We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genesis Biopharma and Lonza Partner form Partnership
News

Genesis Biopharma and Lonza Partner form Partnership

Genesis Biopharma and Lonza Partner form Partnership
News

Genesis Biopharma and Lonza Partner form Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genesis Biopharma and Lonza Partner form Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genesis Biopharma, Inc., and Lonza have announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

Contego™ is a ready-to-infuse cell therapy based on currently available therapies at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.

"We are pleased to have such an experienced bioprocess development and manufacturing partner as Lonza," stated Mr. Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma.

"Lonza is pleased to be in partnership with Genesis Biopharma, and to bring expertise in large-scale autologous cell therapy production to the task of making Contego™ widely available to patients suffering from metastatic melanoma," said David Smith, Head of Therapeutic Cell Solutions at Lonza.

Advertisement